ArticleMalaria journal2026
Defining safety parameters for first-trimester malaria treatment trials: stakeholder views from Real-Time Delphi survey.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundIn 2022, the World Health Organisation recommended artemether-lumefantrine as the first-line treatment for uncomplicated malaria in first-trimester pregnancy. However, emerging drug resistance and WHO's recommendation for treatment diversification necessitate research on alternative artemisinin-based combination therapies (ACTs). We conducted a Real-Time (RT) Delphi survey to establish stakeholder views on safety endpoints and non-inferiority margins for a randomised controlled trial evaluating ACTs in first-trimester pregnancy.
methodsAn international RT Delphi study was conducted between September and October 2024, including clinical researchers, regulators, policymakers, ethicists, and healthcare practitioners. Stakeholders completed an online survey, rating the importance of composite endpoints and maternal and infant safety-related outcomes on a 5-point Likert scale. Outcomes were ranked, and acceptable non-inferiority safety margin were explored. Quantitative responses were summarised descriptively, and free-text comments were analysed thematically.
resultsOf the 54 stakeholders invited, 30 responded (56%). Most (23/30, 77%) agreed that a composite safety endpoint consisting of miscarriage, stillbirth, and major congenital anomalies was informative for evaluating ACT safety in the first trimester. Maternal outcomes rated as critical included maternal death (27/30, 90%), severe maternal anaemia (23/30, 77%), renal failure (20/30, 67%), and maternal intensive care admission (19/29, 66%). For infant outcomes, major congenital anomalies (28/30, 94%), stillbirth (26/30, 87%), and neonatal death (25/30, 83%) were considered essential. Most respondents endorsed a non-inferiority margin of HR = 1.2 as a pragmatic balance between trial feasibility and acceptable uncertainty around safety. Qualitative analysis highlighted support for the composite endpoint to address competing risks. However, concerns were raised regarding the non-specificity of some outcomes, such as preterm birth and small-for-gestational-age, which may be influenced by factors unrelated to treatment.
conclusionsThis study provides a framework for researchers to determine key safety outcomes and acceptable non-inferiority margins for malaria treatment trials in the first trimester. Incorporating stakeholder perspectives into trial design can support evidence-informed policy and facilitate the deployment of a wider range of antimalarial treatments considered safe in early pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.